Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus dendritic cell vaccine maintenance for extensive-stage small cell lung cancer
2024-518636-36-00Phase 2Completed
- Sponsor
- Instituto Oncológico Dr. Rosell
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and autologous dendritic cell vaccine loaded with tumor lysate in small cell lung cancer (SCLC), sponsored by Instituto Oncológico Dr. Rosell. Primary endpoint: Progression-free survival rate at 6 months. Started Oct 2024; status: completed.
02
Drugs
atezolizumabautologous dendritic cell vaccine loaded with tumor lysate
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2024-518636-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518636-36-00.